血管生成抑制剂与抗血管生成疗法的必要性。
Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
作者信息
Dass C R, Tran T M N, Choong P F M
机构信息
Department of Orthopaedics, University of Melbourne, St. Vincent's Health, P.O. Box 2900, Fitzroy, 3065, Melbourne, Australia.
出版信息
J Dent Res. 2007 Oct;86(10):927-36. doi: 10.1177/154405910708601005.
Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.
血管生成是指从已有的血管形成新的血管以构成毛细血管网络，这一过程在肿瘤生长和转移中尤为重要，在诸如糖尿病性视网膜病变和黄斑变性等其他疾病中也发挥作用。因此，自20世纪70年代提出通过抗血管生成药物剥夺肿瘤的血管供应以来，这一方法一直备受关注。本文综述了常见的血管生成抑制剂（血管抑素、内皮抑素、乳珠蛋白、色素上皮衍生因子、贝伐单抗及其他单克隆抗体，以及唑来膦酸）及其在临床试验中的现状。
Zotero 插件